Dysthymic disorder: Implications for diagnosis and treatment

Current Opinion in Psychiatry

Volumn 12, Issue 1, 1999, Pages 69-75

  Rihmer, Zoltán ^a  

^a NATIONAL INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; IMIPRAMINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

CHRONIC DISEASE; COMORBIDITY; DEPRESSION; DISEASE CLASSIFICATION; DYSTHYMIA; HUMAN; PSYCHOTHERAPY; REVIEW;

EID: 0032996790     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-199901000-00020     Document Type: Review

References (48)

1. Akiskal HS. Overview of chronic depressions and their clinical management. In: Dysthymia and the spectrum of chronic depressions. Akiskal HS, Cassano GB (editors). New York: The Guilford Press; 1997. pp. 1-34. This chapter provides an excellent historical discussion of traditional chronic depressive diagnostic concepts and summarizes scientific evidence that has resulted in a new concept of dysthymic disorder and related chronic depressions.
2. Angst J. The prevalence of depression. In: Antidepressant therapy at the dawn of the third milleneum. Briley M, Montgomery SA (editors). London: Martin Dunitz Ltd; 1998. pp. 191-212. In this detailed review the author summarizes the world literature on the prevalence of major depression, minor depression, dysthymic disorder and recurrent brief depression with special attention to their comorbidity.
3. Shelton RC, Davidson JD, Yonkers KA, Koran L, Thase ME, Pearlstein T, et al. The undertreatment of dysthymia. J Clin Psychiatry 1997; 58:59-65. The fact that 57% of the 410 DSM-III-R primary, early-onset dysthymic patients reported family history of affective disorder in first degree relatives and that 51% of them had previous history of major depression also supports the strong relationship between dysthymic disorder and major depression. The most common comorbid axis I nonmood disorders were substance use disorder and panic disorder, and more than half of the dysthymic patients had comorbid Axis II personality disorders.
4. The WPA Dysthymia Working Group. Dysthymia in clinical practice. Br J Psychiatry 1995; 166:174-183.
5. Akiskal HS. Dysthymic disorder: psychopathology of proposed chronic depressive subtypes. Am J Psychiatry 1983; 140:11-20.
6. Akiskal HS, Judd LL, Gillin JC, Lemmi H. Subthreshold depressions: clinical and polysomnographic validation of dysthymic, residual and masked forms. J Affect Dis 1997; 45:53-63. In this article Akiskal et al. discuss their highly stimulative clinical and polysomnographic findings published from the late 1970s that support a common genetic background and neurobiological substrate for low-grade, chronic or intermittent depressions, as well as classical, major (melancholic) mood disorders.
7. Howland RH, Thase ME. Biological studies of dysthymia. Biol Psychiatry 1991; 30:283-304.
8. Rihmer Z, Szádóczky E. Dexamethason suppression test and TRH-TSH test in subaffective dysthymia and character spectrum disorder. J Affect Dis 1993; 28:287-291.
9. American Psychiatric Association. Diagnostic and statistical manual for mental disorders, 3rd edn. Washington, DC: American Psychiatric Press; 1980.
10. American Psychiatric Association. Diagnostic and statistical manual for mental disorders. 3rd rev edn. Washington, DC: American Psychiatric Press; 1987.
11. American Psychiatric Association. Diagnostic and statistical manual for mental disorders. 4th edn. Washington, DC: American Psychiatric Press; 1994.
12. Giles DE, Biggs MM, Roffwarg HP, Orsulak PJ, Rush JA. Secondary depression: a comparison among subtypes. J Affect Dis 1987; 12:251-258.
13. Pepper CM, Klein DN, Anderson RL, Riso LP, Ouimette PC, Lizardi H. DSM- III-R Axis II comorbidity in dysthymia and major depression. Am J Psychiatry 1995; 152:239-247.
14. Black KJ, Sheline YI. Personality disorder scores improve with effective pharmacotherapy of depression. J Affect Dis 1997; 43:11-18.
15. Baving L, Maes H, Bohus M, Lis S, Krieger S, Olbrich H, et al. Can negative self-schemes in depressives be altered through sleep deprivation? J Affect Dis 1997; 42: 93-101.
16. World Health Organization. ICD-10 classification of mental and behavioural disorders. Geneva: World Health Organization; 1992.
17. Klein DN, Riso LP, Donaldson SK, Schwartz JE, Anderson RL, Ouimette PC, et al. Family study of early-onset dysthymia. Mood and personality disorders in relatives of outpatients with dysthymia and episodic major depression and normal controls. Arch Gen Psychiatry 1995; 52:487-496.
18. Kovacs M, Akiskal HS, Gatsonis C, Parrone PL. Childhood-onset dysthymic disorder. Clinical features and prospectve naturalistic outcome. Arch Gen Psychiatry 1994; 51:365-374.
19. Thase ME. Antidepressant treatment of dysthymia and related chronic depressions. Curr Opin Psychiatry 1998; 11:77-83. This is a comprehensive review of the literature, focusing mainly on publications that appeared after 1996. The author also gives a brief account of the role of psychotheraphies in the treatment of dysthymic disorder.
20. Ravindran AV, Chudzik J, Bialik RJ, Lapierre YD, Hrdina PD. Platelet serotonin measures in primary dysthymia. Am J Psychiatry 1994; 151:1369- 1871.
21. Ravindran AV, Bialik RJ, Lapierre YD. Primary early onset dysthymia, bichemical correlates of the therapeutic response to fluoxetine: I. Platelet monoamine oxidase and the dexamethasone suppression test. J Affect Dis 1994; 31:111-117.
22. Szádóczky E, Papp Zs, Vitrai J, Rihmer Z, Füredi J. The prevalence of major depressive and bipolar disorders in Hungary. J Affect Dis (in press). This is the first study to use a standardized, internationally accepted instrument to estimate the prevalence of affective disorders in the general population of Hungary. The lifetime rates of major depression and bipolar disorder were found to be 15.1% and 5.1%, respectively.
23. Szádóczky E, Rihmer Z, Papp Zs, Füredi J. The prevalence of affective and anxiety disorders in primary care practice in Hungary. J Affect Dis 1997;43: 239-244.
24. Værøy H, Merskey H. The prevalence of current major depression and dysthymia in a Norwegian general practice. Acta Psychiatr Scand 1997; 95:324-328. It should be noted that out of the high number of patients with DSM-III-R major depression at the time of the investigation (28 patients, 28%) only six had previously been diagnosed as depressed.
25. Canals J, Domènech E, Carbajo G, Bladé J. Prevalence of DSM-III-R and ICD-10 psychiatric disorders in a Spanish population of 18-year-olds. Acta Pychiatr Scand 1997; 96:287-294. Of the individuals studied, 30% reported at least one current psychiatric disorder according to ICD-10 criteria, whereas the same figure according to DSM-III-R was 21%. Dysthymic disorder and major depression were among the most common illnesses, and about 40% of the diagnosed individuals had one or more comorbid disorders.
26. Wittchen H-U, Nelson CB, Lachner G. Prevalence of mental disorders and psychological impairments in adolescents and young adults. Psychol Med 1998; 28:109-126. It is interesting to note that 3.4% of the individuals had lifetime history of bipolar and 11.8% of unipolar major depressive disorder. The most frequent DSM-IV psychiatric diagnosis in this population, however, was substance use disorder (lifetime prevalence 18%).
27. Devanand DP, Nobler MS, Singer T, Kiersky JE, Turret N, Roose SP, et al. Is dysthymia a different disorder in the elderly? Am J Psychiatry 1994; 151:1592-1599.
28. Donaldson SK, Klein DN, Riso LP, Schwartz JE. Comorbidity between dysthymic and major depressive disorders: a family study analysis. J Affect Dis 1997; 42:103-111.
29. Judd LL. Pleomorphic expressions of unipolar depressive disease: summary of the 1996 CINP President's Workshop. J Affect Dis 1997; 45:109-116. The statements of this paper are based on the extensive research - in most cases, the life works - of the best recognized experts in the field of mood disorders. It, as well as other articles contained in this special issue of Journal of Affective Disorders, are warmly recommended for everyone interested in the diagnosis and treatment of the wide spectrum of depressive disorders.
30. Pini S, Cassano GB, Simonini E, Savino M, Russo A, Montgomery SA. Prevalence of anxiety disorders comorbidity in bipolar depression, unipolar depression and dysthymia. J Affect Dis 1997; 42:145-153.
31. Sansone RA, Wiederman MW, Sansone LA, Touchet B. Early-onset dysthymia and personality disturbance among patients in a primary care setting. J Nerv Ment Dis 1998; 186:57-58. This brief report is the first to demonstrate substantial personality disorder comorbidity among early-onset dysthymic disorder patients in primary care population, ruling out comorbidity as a reflection of the selection bias in various psychiatric settings.
32. Shores MM, Glub T, Cowley DS, Dager SR, Roy-Bryne PP, Dunner DL. The relationship between anxiety and depression: a clinical comparison of generalised anxiety disorder, dysthymic disorder, panic disorder and major depressive disorder. Comp Psychiatry 1992; 33:237-244.
33. Sanderson WC, Wetzler S, Beck AT, Setz F. Prevalence of personality disorders in patients with major depression and dysthymia. Psychiatry Res 1992; 42:93-99.
34. Piccinelli M. Comorbidity of depression and generalized anxiety: is there any distinct boundary? Current Opinion in Psychiatry. 1998; 11:57-60. This article reviews the relationship between depression and GAD, with special attention to genetic, enviromental, clinical and pharmacological aspects.
35. Ohrt T, Thorell L-H, Sjödin I, d'Elia G. Are dysfunctional attitudes in depressive disorder trait or state dependent? Acta Psychiatr Scand. 1998; 97:419-422. In this study, the authors compared the dysfunctional attidude scale scores of 79 lithium-treated (euthymic) recurrent unipolar depressives and 79 matched healthy control. They found no difference between the two groups, which suggests that individuals social dysfunction is a state dependent variable (i.e. the consequence) of major depression.
36. Tripodianakis J, Markianos M, Sarantidis D, Spyropoulou G, Taktikou V, Bistolaki E. Platelet MAO activity in patients with dysthymic disorder. Psychiatry Res 1998; 78.173-178. The authors investigated the platelet MAO activity in 58 patients with DSM-III-R dysthymic disorder and in 61 healthy control individuals. Female, but not male, patients showed significantly lower enzyme activity than (female) control individuals. The platelet MAO activity did not correlate with age, duration of illness and severity of dysthymic disorder, but female patients with history of suicide attempt were found to have the lowest enzyme activity.
37. Naga Venkatesha Murthy PJ, Gangadhar BN, Janakiramiah N, Subbakrishna DK. Normalization of P300 amplitude following treatment in dysthymia. Biol Psychiatry 1997; 42:740-743. In contrast to P300 amplitude, the P300 latency of dysthymics and major depressives was in the normal range and did not change after treatment.
38. Lecrubier Y. Pharmacological interventions in dysthymia. Eur Psychiatry 1996; 11 (Suppl 3):129-133.
39. Invemizzi G, Mauri MC, Waintraub L. Antldepressant efficacyin the treatment of dysthymia. Eur Neuropsychopharmacol 1997; 7 (suppl 3):S329-S336.
40. Semeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission. A double-blind, comparative study. J Affect Dis 1998; 48:47-56. The result that dopaminergic manipulations are also effective in dysthymic disorder is important from the theoretical point of view also, and further studies are needed to explore the role of dopamine metabolism in mood disorders.
41. Levitt AJ, Joffe RT, Sokolov STH. Does the chronological relationship between the onset of dysthymia and major depression influence subsequent response to antidepressants? J Affect Dis 1998; 47:169-175. The first treatment in this study was desipramine in each case for 5 weeks. Nonresponders received augmentation with tri-iodothyronine or with lithium for 2 weeks. If this was unsuccessfull, the patients were switched to a selective serotonin reuptake inhibitor for further 5-6 weeks. Treatment response was estimated at the end of the last drug trial.
42. Versiani M, Amrein R, Stabl M. Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled study. Int Clin Psycopharmacol 1997; 12:183-193.
43. Dunner DL, Hendrickson HE, Bea C, Budech CB. Venlafaxine in dysthymic disorder. J Clin Psychiatry 1997; 58:528-531. There were two response patterns among the 10 responders; seven patients responded quickly to low dose, whereas the remaining three required the maximum dose and responded slowly.
44. Markowitz JC. Psychoteraphy of dysthymia. Am J Psychiatry 1994; 151:1114-1121.
45. Laakmann G, Schüle C, Baghai T, Kieser M. St John's Wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 1998; 31 (Suppl):54-59. This paper, together with several others in the same supplement volume of this journal, offers a comprehensive overview on the biochemistry and clinical effectiveness of the extract of St John's Wort.
46. Volz H-P. Controlled clinical trials of hypericum extracts in depressed patients - an overview. Pharmacopsychiatry 1997; 30 (Suppl):72-76. It should be noted that the diagnosis of many patients included in this review [i.e. mild depression (ICD-9: 300.4)] may correspond to dysthymic disorder as classified in DSM-IV.
47. Müller WE, Rolli M, Schäfer C, Hafner G. Effects of hypericum extract (LI 160) in bichemical models of antidepressant activity. Pharmacopsychiatry 1997; 30 (Suppl):102-107. The authors, having tested the mechanisms of action of hypericum extract in several well accepted biochemical models, found a weak inhibitory effect on MAO-A and MAO-B as well as clear reuptake inhibition of serotonin, noradrenaline and dopamine. In addition, subchronic trteatment resulted in significant down-regulation of beta receptors and significant upregulation of serotonin-2 receptors.
48. Naga Venkatesha Murthy PJ, Janakiramiah N, Gangadhar BN, Subbakrishna DK. P300 amplitude and antidepressant response to Sudarshan Kriya Yoga (SKY). J Affect Dis 1998; 50:45-48. The majority of 15 dysthymic individuals and 15 melancholic individuals showed decreased P300 amplitude, whereas this state-dependent biologic marker failed to predict the response to the treatment.